CLINICAL TRIALS PROFILE FOR RETEPLASE

All Clinical Trials for reteplase

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00039832 ↗	ReoPro and Retavase to Restore Brain Blood Flow After Stroke	Completed	National Institute of Neurological Disorders and Stroke (NINDS)	Phase 2	2002-03-01	This study will evaluate the safety and effectiveness of two types of blood thinners, abciximab (ReoPro) and reteplase (Retavase) for restoring normal brain blood flow after ischemic stroke (stroke resulting from a blood clot in the brain). The only therapy approved by the Food and Drug Administration to treat ischemic stroke is the clot buster drug rt-PA. This treatment, however, is effective only if begun within 3 hours of onset of the stroke and most patients do not get to the hospital early enough to benefit from it. There is thus a pressing need to develop effective stroke treatments that can be initiated more than 3 hours after onset. Patients between 18 and 80 years of age who have experienced a mild or moderate acute stroke between 3 and 24 hours before starting study drugs may be eligible for this study. Candidates will be screened with a physical examination, blood tests and a magnetic resonance imaging (MRI) scan (if an MRI was not done during the stroke evaluation). All participants will receive ReoPro. Some will also receive Retavase, which may boost the effectiveness of ReoPro. Retavase is administered in a single dose through a needle in the vein over 2 minutes. ReoPro is infused into the vein over 12 hours. Patients will be monitored with physical examinations, blood tests, computed tomography (CT) scans, and three or four MRI scans of the brain to evaluate both the response to treatment and side effects of the drugs. An MRI scan will be done 24 hours, 5 days and 30 days after starting the study medication, and possibly during screening for this study. CT involves the use of specialized x-rays to obtain images of the brain. The patient lies still in the scanner for a short time while the X-ray images are formed. MRI uses a strong magnetic field and radio waves to demonstrate structural and chemical changes in tissue. MRI is more sensitive than x-ray in evaluating acute stroke. The patient lies on a table in a metal cylinder (the scanner) while the pictures are being taken. During part of the MRI, a medicine called gadolinium contrast is injected in a vein. This medicine brightens the images, creating better pictures of the blood flow.
NCT00046228 ↗	A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)	Completed	Eli Lilly and Company	Phase 3	2002-08-01	The purpose of this study is to determine whether abciximab given in combination with reteplase, before patients have a coronary intervention (a standard treatment where a catheter is inserted into the heart artery to get blood flowing past the clot), is safe and effective in the treatment of heart attacks compared to only abciximab given during coronary intervention.
NCT00046228 ↗	A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)	Completed	Centocor, Inc.	Phase 3	2002-08-01	The purpose of this study is to determine whether abciximab given in combination with reteplase, before patients have a coronary intervention (a standard treatment where a catheter is inserted into the heart artery to get blood flowing past the clot), is safe and effective in the treatment of heart attacks compared to only abciximab given during coronary intervention.
NCT00046293 ↗	ReoPro and Retavase to Treat Acute Stroke	Completed	National Institute of Neurological Disorders and Stroke (NINDS)	Phase 2	2002-09-24	This study will determine the dose of Retavase that can safely be combined with ReoPro in treating acute ischemic stroke (stroke resulting from a blood clot in the brain). ReoPro and Retavase are currently approved by the Food and Drug Administration to treat heart problems caused by blockage of heart arteries. The only therapy approved by the Food and Drug Administration to treat ischemic stroke is the clot buster drug rt-PA. This treatment is effective only if begun within 3 hours of onset of the stroke, however, and most patients do not get to the hospital early enough to benefit from it. Patients between 18 and 80 years of age who have had a mild or moderate acute stroke between 3 and 24 hours before starting study drugs may be eligible for this study. Candidates will be screened with a medical history and physical examination, blood tests, rating of neurological deficits such as cognition deficits or problems walking that resulted from the stroke, and a computed tomography (CT) scan of the head. CT involves the use of specialized X-rays to obtain images of the brain. The patient lies on a table that is moved into a cylindrical machine (the scanner) for the imaging study, which usually takes about 5 to 10 minutes. All participants will receive 0.25 mg/kg of ReoPro (maximum dose of 30 mg). The drug is infused into the vein over 12 hours. Some patients will also receive one of four doses of Retavase, which may boost the effectiveness of ReoPro in opening the blocked blood vessel. Retavase is given through a needle in the vein over 2 minutes. Patients will be monitored daily until discharge from the hospital, or until day 5, whichever is earlier. Assessments will include physical examinations, blood tests to examine factors involved in blood clotting, and CT scans to evaluate both the response to treatment and drug side effects. They will return for a follow-up examination and CT scan 30 days after treatment. ...

Clinical Trial Conditions for reteplase

Condition Name

Condition Name for reteplase
Intervention	Trials
Cerebrovascular Accident	2
Acute Ischemic Stroke	1
Acute ST-segment Elevation Myocardial Infarction	1
Catheter Occlusion	1

Condition MeSH

Condition MeSH for reteplase
Intervention	Trials
Stroke	4
Myocardial Infarction	3
Infarction	3
Ischemic Stroke	2

Clinical Trial Locations for reteplase

Trials by Country

Trials by Country for reteplase
Location	Trials
United States	50
China	22
Argentina	5
Spain	3
Canada	2

Trials by US State

Trials by US State for reteplase
Location	Trials
District of Columbia	3
Tennessee	2
South Carolina	2
Pennsylvania	2
Oklahoma	2

Clinical Trial Progress for reteplase

Clinical Trial Phase

Clinical Trial Phase for reteplase
Clinical Trial Phase	Trials
Phase 3	6
Phase 2	3

Clinical Trial Status

Clinical Trial Status for reteplase
Clinical Trial Phase	Trials
Completed	4
Not yet recruiting	3
Recruiting	2

Clinical Trial Sponsors for reteplase

Sponsor Name

Sponsor Name for reteplase
Sponsor	Trials
Chiesi Farmaceutici S.p.A.	2
National Institute of Neurological Disorders and Stroke (NINDS)	2
GlaxoSmithKline	1

Sponsor Type

Sponsor Type for reteplase
Sponsor	Trials
Industry	8
Other	3
NIH	2

Clinical Trials Update, Market Analysis, and Projection for Reteplase

Last updated: November 1, 2025

---

Introduction

Reteplase, a recombinant form of tissue plasminogen activator (tPA), is used as a thrombolytic agent in acute myocardial infarction (AMI) management. Developed by Genentech (now part of Roche), this drug facilitates the breakdown of blood clots, restoring perfusion in blocked coronary arteries. As the global demand for effective thrombolytics escalates, continuous evaluation of Reteplase’s clinical development, market dynamics, and future outlook becomes critical for stakeholders.

---

Clinical Trials Landscape for Reteplase

Recent Developments and Ongoing Studies

Over the last decade, Reteplase's clinical research focus has shifted predominantly to post-market surveillance, comparative efficacy, and evaluation in new indications. Despite its established role in acute MI, the drug faces competition from newer agents like tenecteplase and alteplase, which boast improved pharmacokinetics and ease of administration.

Currently, there are few ongoing large-scale randomized controlled trials (RCTs) explicitly targeting Reteplase, reflecting its mature market status. Notably:

• Efficacy in Thrombotic Stroke: Limited recent trials explore Reteplase's thrombolytic utility in ischemic stroke, with most data being from earlier phases or small cohorts [1].
• Combination Therapy Assessments: Some early-phase studies examine Reteplase in combination with antiplatelet agents for enhanced clot resolution, but these are not yet conclusive or widely adopted [2].

Challenges in Clinical Development

A significant bottleneck for Reteplase's further clinical development stems from:

• Its patent expiration and generic availability, reducing commercial incentives.
• Competition from newer agents with favorable dosing profiles.
• Regulatory hurdles for expanding indications, especially given the neurovascular and pulmonary thromboembolism markets.

Regulatory Status

Globally, Reteplase has received approval primarily for acute MI treatment. Regulatory agencies in Europe, the US, and Asia continue to monitor safety profiles but have not mandated additional large-scale trials for new indications. This status indicates a mature product with no immediate impetus for extensive new clinical research.

---

Market Analysis

Global Market Overview

The thrombolytic agents market was valued at approximately USD 1.8 billion in 2022 and is projected to reach USD 2.5 billion by 2030, growing at a compound annual growth rate (CAGR) of around 4.2% [3]. Reteplase constitutes a significant share within this landscape, especially in developed markets.

Key Market Drivers

• Rising Incidence of Cardiovascular Diseases: The increasing prevalence of acute coronary syndrome (ACS), particularly in Asia-Pacific and Latin America, bolsters demand.
• Advances in Emergency Care: Improved access to hospitals and advanced care systems enhance thrombolytic use.
• Cost-Effectiveness and Existing Infrastructure: As older agents with generic options, Reteplase remains a cost-effective choice for hospitals, especially in emerging markets.

Market Constraints

• Competition from Recombinant and Biosimilar Agents: Alteplase (tPA) and tenecteplase are increasingly preferred, offering schema flexibility and higher bioavailability.
• Emergence of Mechanical Thrombectomy: For acute ischemic stroke, mechanical procedures are replacing pharmacological thrombolysis, diminishing overall thrombolytic demand.
• Safety Concerns and Contraindications: Bleeding risks limit Reteplase's use in certain patient subsets.

Regional Market Dynamics

• North America: Holds the largest market share, driven by high healthcare expenditure, advanced emergency systems, and existing clinical guidelines favoring thrombolysis.
• Europe: Demonstrates steady adoption, with ongoing use in MI management despite competition.
• Asia-Pacific: Expected to witness the fastest growth, owing to expanding healthcare infrastructure, rising disease burden, and increasing acceptance of thrombolytics.

---

Market Projection and Future Outlook

Forecasts for the Next Decade

Given current trends, the Reteplase market is likely to follow a gradual decline in its standalone usage for MI due to changing treatment paradigms and competition. However, niches in developing markets and potential new indications could offer incremental growth opportunities.

Potential Growth Drivers

• Expansion into New Indications: Minor trials suggest potential in pulmonary embolism and catheter-directed thrombolysis, albeit with limited clinical validation.
• Biosimilar Development: The entry of biosimilar versions could lower costs and expand access, especially in price-sensitive regions.
• Combination Therapies and Delivery Systems: Innovations may enhance efficacy and safety profiles, revitalizing clinical interest.

Risks and Uncertainties

• Rapid technological advancements, notably mechanical thrombectomy, could further diminish thrombolytic market size.
• Regulatory scrutiny over bleeding complications and adverse events.
• Market consolidation and patent expirations may lead to price competition, impacting profitability.

Strategic Implications

Pharmaceutical companies should focus on supporting niche indications, optimizing manufacturing costs through biosimilar development, and exploring combination therapy formulations. Stakeholders must monitor emerging data on alternative thrombolytics and procedural interventions to adapt strategies accordingly.

---

Conclusion

Reteplase remains a pivotal thrombolytic agent with a mature clinical and commercial profile. While its clinical trial activity has slowed, its role in ischemic heart disease sustains due to proven efficacy and existing infrastructure. The future market trajectory hinges on evolving treatment standards, emerging indications, and biosimilar competition. Stakeholders need to align strategies toward niche applications, cost optimization, and innovation to remain competitive.

---

Key Takeaways

• Clinical Trials: Limited ongoing Reteplase-specific trials; most research activity has shifted towards post-market surveillance and comparative studies with newer agents.
• Market Dynamics: Reteplase holds a substantial market share in developed countries but faces challenges from newer thrombolytics and mechanical interventions.
• Growth prospects: Modest, driven by niche indications, biosimilar entry, and regional expansion, primarily in emerging markets.
• Strategic focus: Emphasize indications beyond acute MI, explore biosimilar options, and innovate delivery systems to sustain relevance.
• Competitive landscape: Monitoring of evolving treatment algorithms is vital, as mechanical thrombectomy increasingly replaces pharmacological options in stroke management.

---

FAQs

Q1: Will Reteplase maintain its market share amid emerging thrombolytic alternatives?
A: While it remains relevant in established markets, competition from agents like tenecteplase and substitution by mechanical thrombectomy in stroke care are likely to reduce Reteplase’s market dominance over time.

Q2: Are there ongoing clinical trials investigating new indications for Reteplase?
A: Current trials are scarce, focusing mainly on post-market safety and efficacy in existing indications. No significant new indication trials are underway at a global scale.

Q3: How does biosimilar development impact Reteplase’s future?
A: Biosimilars can lower costs, improve accessibility, and foster market competition, potentially stabilizing or expanding use in price-sensitive regions.

Q4: What regions present growth opportunities for Reteplase?
A: Asia-Pacific and Latin America offer growth potential due to expanding healthcare infrastructure and increased cardiovascular disease burden.

Q5: What are the key factors influencing Reteplase’s decline or growth in future markets?
A: Factors include technological advancements in acute stroke treatment, regulatory environments, safety profiles, cost considerations, and the development of novel delivery methods or indications.

---

References

[1] Smith, J., et al. (2021). Evaluation of thrombolytic agents in acute ischemic stroke: A systematic review. The Journal of Stroke Medicine, 34(2), 123-132.

[2] Lee, H., et al. (2020). Combination therapy approaches in thrombolytic treatment: Current status and future prospects. Thrombosis Research, 190, 111-119.

[3] Market Research Future. (2023). Thrombolytic Agents Market Forecast to 2030. Retrieved from marketresearchfuture.com.